|
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes |
Mar 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Morphologic Characteristics of Myelodysplastic Syndromes |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
|
Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
|
Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
|
Transfusion Support of Patients with Myelodysplastic Syndromes |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
|
Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53 |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
|
Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis. |
Jan 2019 |
Crit Rev Oncol Hematol |
Myelodysplastic Syndromes (MDS) |
|
Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant. |
Jan 2019 |
Crit Rev Oncol Hematol |
Myelodysplastic Syndromes (MDS) |
|
Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia |
Jul 2020 |
Critical reviews in hematology/oncology |
Myelodysplastic Syndromes (MDS) |
|
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS |
Jun 2019 |
Current Hematologic Malignancy Report |
Myelodysplastic Syndromes (MDS) |
